Hyperliquid Strategies Inc.

What they do

The company operates as a treasury vehicle for HYPE, accumulating and staking HYPE tokens to generate revenue. It has completed the disposition of the majority of its legacy bio-tech operations and is building a validator partnership with Unit, a Hyperliquid deployer.

Revenue drivers

• Staking revenue — Generates $3.1 million in staking revenue for the nine months ended March 31, 2026, with $2.6 million in the latest quarter.
• Interest income — Earned $1.9 million in interest income over nine months and $1.0 million in the latest quarter.
• HYPE token holdings — Core asset base of 18.83 million HYPE tokens at quarter-end, valued at $689.0 million; treasury increased to 20.0 million HYPE tokens as of April 29, 2026.

Recent performance

For the three months ended March 31, 2026, the company reported $2.6 million in staking revenue and $1.0 million in interest income, with $7.2 million in SG&A and R&D expenses. Net profit was $152.5 million, driven by $198.4 million in unrealized gains on HYPE tokens, partially offset by a $42.7 million deferred tax expense increase. For the nine months, staking revenue was $3.1 million and interest income $1.9 million, but SG&A and R&D expenses totaled $10.7 million. The nine-month net loss was $165.4 million, largely due to $64.0 million in net unrealized losses on HYPE tokens, a one-time $35.6 million IPR&D write-off, and a $60.5 million deferred tax expense increase. Total assets were $809.4 million, including $113.1 million cash and $689.0 million in HYPE tokens, with no debt.

Strategy

The company is focused on deepening alignment with Hyperliquid's deflationary mechanics and ecosystem expansion. It has deployed $216.0 million to accumulate ~7.3 million HYPE tokens since inception, increasing total holdings to 20.0 million. It also repurchased ~3.0 million PURR shares at an average cost of $3.42 per share. The company issued $38.4 million in PURR shares under a committed equity facility at an average price of approximately $6.31. Management highlights Hyperliquid's HIP-3 RWA perps, portfolio margin, and outcome markets as drivers for potential growth.

Risks

• HYPE token price volatility — Quarterly results swing significantly with unrealized gains/losses on HYPE tokens, as shown by a $152.5 million net profit in Q3 versus a $165.4 million nine-month net loss.
• Deferred tax expense variability — Large deferred tax expense increases ($60.5 million for nine months, $42.7 million for the quarter) can materially impact reported net income.
• Concentration risk — The balance sheet is heavily concentrated in a single digital asset, HYPE, which represented $689.0 million of $810.4 million total assets.
• Legacy biotech disposition — The completed disposition of the majority of legacy bio-tech operations may involve ongoing liabilities or integration issues, though details are not fully disclosed.

Outlook

Management expresses optimism about Hyperliquid's trajectory, citing HIP-3 RWA perps, portfolio margin, and outcome markets as potential drivers for sustained growth and fee generation. The treasury has been increased to 20.0 million HYPE tokens with $103 million in cash remaining as of April 29, 2026. The company plans to continue disciplined capital deployment and grow staking revenue.